Dec. 27, 2012
/PRNewswire/ -- American Capital, Ltd. (Nasdaq: ACAS) ("American Capital") announced today that it has committed
in the One Stop Buyout® of Cambridge Major Laboratories, Inc. ("CML" or the "Company"), a leading global provider of complex chemistry-based outsourcing services to the pharmaceutical and biotechnology industries. CML expands American Capital's portfolio of healthcare products and services companies, which have aggregate revenues of over
. American Capital's investment took the form of debt and preferred and common equity. Jefferies & Company, Inc., served as sole financial advisor to CML on the transaction. CML was a portfolio company of Arlington Capital Partners prior to American Capital's investment.
, CML is an active pharmaceutical ingredient ("API") development and manufacturing organization serving a broad customer base of pharmaceutical, biotech and generic drug companies. The Company operates from FDA inspected facilities in the U.S. and Europe. In 2012, the Company developed and supplied over 100 APIs for drugs in the early and mid-stages of development and 14 APIs for drugs that are commercially available. The products CML manufactures span a wide range of therapeutic categories from cancer to neurology to rare genetic diseases.
"CML has experienced substantial growth since inception due to the Company's continued expansion of its service offerings, operations and facilities," said
, Principal, American Capital Buyouts Group. "As a result, CML is now a market leader across the entire spectrum of drug development and commercialization, providing services and products to customers with early-stage, late-stage and commercial compounds. The Company's market position, complex chemistry abilities, outstanding execution of its service offerings and large state-of-the-art facilities, both in the U.S. and
, will allow CML to continue to meet the increased outsourcing demand from pharmaceutical and biotech companies. We look forward to working with CML's management team to substantially grow the Company, both organically and through acquisitions."
"CML's management team has significant experience and expertise in the chemistry research, manufacturing and pharmaceutical industries in addition to an impressive track record of delivering sustainable growth," said
, Vice President, American Capital Buyouts Group. "American Capital is pleased to work with CML's seasoned management team in the next phase of the Company's growth."
"The management team at CML chose to partner with American Capital due to their ability to finance the entire transaction as well as their knowledge and expertise in growing companies within the life sciences industry," said
, President and CEO of CML. "American Capital's financial and operational resources will allow us to expand our market presence in the U.S. and internationally. We look forward to working with American Capital's impressive portfolio of pharmaceutical services companies that will fully compliment CML's service offering."
American Capital and its affiliated funds have invested approximately
in over 540 portfolio companies both directly and in support of leading financial partners in change of control transactions. For more information about American Capital's portfolio, go to
ABOUT AMERICAN CAPITAL
American Capital is a publicly traded private equity firm and global asset manager. American Capital, both directly and through its asset management business, originates, underwrites and manages investments in middle market private equity, leveraged finance, real estate and structured products. American Capital manages
of assets, including assets on its balance sheet and fee earning assets under management by affiliated managers, with
of total assets under management (including levered assets). From its eight offices in the U.S. and
, American Capital and its affiliate, European Capital, will consider investment opportunities from
$10 million to $500 million
. For further information, please refer to
(1) This amount of aggregate revenues is a non-GAAP financial measure and represents the sum of the unaudited revenues of certain American Capital portfolio companies, reflecting various assumptions and practices, which are not necessarily consistently followed or applied. Though majority owned, such companies are not wholly-owned by American Capital and no adjustments have been applied to reflect the ownership of other entities.